Lloyd Industries v. Datrend Systems: Voluntary Dismissal in ESU Analyzer Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Lloyd Industries, Inc. et al. v. Datrend Systems, Inc. |
| Case Number | 1:23-cv-00998 (W.D. Tex.) |
| Court | U.S. District Court for the Western District of Texas |
| Duration | Aug 2023 – Mar 2024 208 days |
| Outcome | Dismissed with Prejudice |
| Patents at Issue | |
| Accused Products | Datrend Systems’ vPad-RF ESU Analyzer |
Case Overview
The Parties
⚖️ Plaintiffs
Both companies operate in the medical equipment testing and safety compliance space, where precision instruments and regulatory alignment are core competitive differentiators.
🛡️ Defendant
A Canadian-based manufacturer known for its line of medical device safety testers and biomedical test equipment.
The Patent at Issue
The asserted patent, **U.S. Patent No. 9,883,903 B1** (Application No. 14/702,385), covers technology relevant to the testing and analysis of electrosurgical unit performance. ESU analyzers measure high-frequency electrical output used in surgical cutting and coagulation equipment, placing this patent squarely within the medical device testing patent landscape — an area experiencing increased enforcement activity as healthcare technology investment grows.
- • US 9,883,903 B1 — Technology for testing and analysis of electrosurgical unit performance
Developing medical device testing equipment?
Check if your product might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
On March 15, 2024, plaintiffs Lloyd Industries and BC Group Int’l filed a notice of voluntary dismissal with prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). The court confirmed closure on March 18, 2024. No damages were awarded, no injunctive relief was issued, and no settlement terms have been publicly disclosed.
Key Legal Issues
The case was filed as a straightforward patent infringement action — no validity challenges, declaratory judgment counterclaims, or IPR petitions appear in the available case record. The dismissal with prejudice, entered before Datrend formally engaged through counsel, raises several strategic questions for practitioners:
- • Pre-answer dismissal dynamics: Under Rule 41(a)(1)(A)(i), a plaintiff retains unilateral dismissal rights before the defendant serves an answer or summary judgment motion. This right disappears once the defendant formally responds, making the timing of Datrend’s non-appearance legally significant.
- • “With prejudice” designation: Unlike a without-prejudice dismissal, this termination bars plaintiffs from re-filing the same claims against Datrend on the same patent. This is a meaningful concession that distinguishes this outcome from a strategic retreat and re-filing.
- • No disclosed settlement: The absence of any disclosed license, settlement, or consent judgment leaves the resolution terms — if any exist — entirely private.
As the court’s order noted, citing In re Amerijet Int’l, Inc., 785 F.3d 967, 973 (5th Cir. 2015): a Rule 41(a)(1)(A)(i) dismissal is “self-effectuating and terminates the case in and of itself; no order or other action of the district court is required.” This procedural mechanism is among the cleanest exits available in federal civil litigation.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in medical device testing equipment. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View relevant patents in the ESU testing space
- Identify key companies active in medical device testing patents
- Understand competitive patenting strategies
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own medical device technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Electrosurgical unit (ESU) analyzer technology
Active Patent
US 9,883,903 B1 remains enforceable
Proactive FTO
Essential for new medical device products
✅ Key Takeaways
Rule 41(a)(1)(A)(i) pre-answer dismissals are self-effectuating — no court order required, but with-prejudice status creates claim preclusion.
Search related case law →Co-plaintiff enforcement structures are increasingly common in specialized technology sectors like medical devices.
Explore competitive intelligence →U.S. Patent No. 9,883,903 B1 remains an active enforcement asset; monitor for future assertions against other ESU analyzer manufacturers.
Track this patent →Frequently Asked Questions
U.S. Patent No. 9,883,903 B1 (Application No. 14/702,385), covering technology relevant to electrosurgical unit testing and analysis.
Plaintiffs voluntarily dismissed under FRCP Rule 41(a)(1)(A)(i) before Datrend served an answer, a self-effectuating procedural right. The with-prejudice designation bars re-filing the same claims against Datrend.
The ‘903 patent remains active and enforceable against third parties. Other ESU analyzer manufacturers should assess FTO exposure; the dismissal provides no safe harbor beyond Datrend.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 1:23-cv-00998 (W.D. Tex.)
- U.S. Patent and Trademark Office — Patent 9,883,903 B1
- United States Court of Appeals for the Fifth Circuit — In re Amerijet Int’l, Inc., 785 F.3d 967, 973 (5th Cir. 2015)
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 41
- PatSnap — AI-native innovation intelligence platform
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.